Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon.
In summary, scientific evidence demonstrates that the rate of serious GI adverse events associated with the use of NSAIDs is comparatively low depending on the definition used, serious GI adverse events occur in 1% of patients each year and occurs in the use of high doses with long-term treatment in chronic conditions. At OTC doses, the incidence of GI adverse events in both adults and children receiving ibuprofen has been shown to be similar to that of paracetamol. Even at prescription doses of ibuprofen, upper GI bleeding is infrequent, and is usually associated with long-term use. Of all the NSAIDs, ibuprofen appears to have one of the best GI tolerability profiles.
Bjarnason
Ingvar
I
Department of Medicine, King's College Hospital, Denmark Hill, London, UK. ingvar.bjarnason@kcl.ac.uk
D000082:Acetaminophen / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage / Q000009:adverse effects*; D004366:Nonprescription Drugs
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004366:Nonprescription Drugs; D000082:Acetaminophen; D007052:Ibuprofen